
Sign up to save your podcasts
Or
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
3.9
1414 ratings
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
11,115 Listeners
39 Listeners
4 Listeners
55 Listeners
7 Listeners
4 Listeners
3 Listeners
1 Listeners
4 Listeners
9 Listeners
41 Listeners
14 Listeners
1 Listeners
46 Listeners
0 Listeners
6 Listeners
493 Listeners
277 Listeners
3,323 Listeners
3 Listeners
87 Listeners
27 Listeners
1,084 Listeners
1,674 Listeners
23 Listeners
350 Listeners
23 Listeners
30 Listeners
364 Listeners
42 Listeners
2 Listeners
0 Listeners
0 Listeners
0 Listeners